These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 35369653)

  • 1. New Vancomycin Dosing Guidelines for Hemodialysis Patients: Rationale, Caveats, and Limitations.
    Lewis SJ; Nolin TD
    Kidney360; 2021 Aug; 2(8):1313-1315. PubMed ID: 35369653
    [No Abstract]   [Full Text] [Related]  

  • 2. Vancomycin dosing and monitoring for patients with end-stage renal disease receiving intermittent hemodialysis.
    Crew P; Heintz SJ; Heintz BH
    Am J Health Syst Pharm; 2015 Nov; 72(21):1856-64. PubMed ID: 26490819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cefazolin in chronic hemodialysis patients: a safe, effective alternative to vancomycin.
    Fogel MA; Nussbaum PB; Feintzeig ID; Hunt WA; Gavin JP; Kim RC
    Am J Kidney Dis; 1998 Sep; 32(3):401-9. PubMed ID: 9740155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation and Development of Vancomycin Dosing Schemes to Meet New AUC/MIC Targets in Intermittent Hemodialysis Using Monte Carlo Simulation Techniques.
    Lewis SJ; Mueller BA
    J Clin Pharmacol; 2021 Feb; 61(2):211-223. PubMed ID: 32851685
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Practical considerations for vancomycin dosing in hemodialysis patients: Perspectives from the nephrology stewardship pharmacist.
    El Nekidy WS; Cha R; Ghazi IM
    Clin Nephrol; 2022 Feb; 97(2):111-120. PubMed ID: 34958297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vancomycin use in patients requiring hemodialysis: a literature review.
    Pallotta KE; Manley HJ
    Semin Dial; 2008; 21(1):63-70. PubMed ID: 18251960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Vancomycin dosing in patients on intermittent hemodialysis.
    Vandecasteele SJ; De Vriese AS
    Semin Dial; 2011; 24(1):50-5. PubMed ID: 21338394
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implementation of a dose calculator for vancomycin to achieve target trough levels of 15-20 microg/mL in persons undergoing hemodialysis.
    Vandecasteele SJ; De Bacquer D; De Vriese AS
    Clin Infect Dis; 2011 Jul; 53(2):124-9. PubMed ID: 21690618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimization of therapeutic drug monitoring of vancomycin in patients with chronic hemodialysis
.
    Mahmoud LB; Chaabouni Y; Ghozzi H; Feriani H; Hakim A; Kharrat M; Marrakchi C; Sahnoun Z; Jmaa MB; Zeghal K; Hachicha J
    Clin Nephrol; 2017 Oct; 88(10):198-204. PubMed ID: 28793955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of weight-based vancomycin dosing for hospitalized hemodialysis patients.
    Maxson R; Pate J; Starr J
    Ren Fail; 2016 Nov; 38(10):1677-1682. PubMed ID: 27756193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of 3 vancomycin dosage regimens during hemodialysis with cellulose triacetate dialyzers: post-dialysis versus intradialytic administration.
    Mason NA; Neudeck BL; Welage LS; Patel JA; Swartz RD
    Clin Nephrol; 2003 Aug; 60(2):96-104. PubMed ID: 12940611
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A protocolized approach to vancomycin dosing in conventional hemodialysis.
    Panais R; Hirsch DJ; Dipchand C; Storsley L; Finkle SN
    J Nephrol; 2010; 23(5):569-74. PubMed ID: 20540035
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of vancomycin in high-flux hemodialysis: experience with 130 courses of therapy.
    Barth RH; DeVincenzo N
    Kidney Int; 1996 Sep; 50(3):929-36. PubMed ID: 8872968
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of vancomycin when administered during high flux hemodialysis.
    Foote EF; Dreitlein WB; Steward CA; Kapoian T; Walker JA; Sherman RA
    Clin Nephrol; 1998 Jul; 50(1):51-5. PubMed ID: 9710347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An updated vancomycin dosing protocol for initiating therapy in patients undergoing intermittent high-flux hemodialysis.
    Zelenitsky SA; Ariano RE
    Am J Health Syst Pharm; 2022 Jun; 79(12):1006-1010. PubMed ID: 35234825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Urea kinetics and dialysis treatment time predict vancomycin elimination during high-flux hemodialysis.
    Schaedeli F; Uehlinger DE
    Clin Pharmacol Ther; 1998 Jan; 63(1):26-38. PubMed ID: 9465839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New hemodialysis membranes and vancomycin clearance.
    Meyer CC; Calis KA
    Am J Health Syst Pharm; 1995 Dec; 52(24):2794-6. PubMed ID: 8748565
    [No Abstract]   [Full Text] [Related]  

  • 18. Evaluation of a vancomycin dosing regimen for patients on high flux hemodialysis: an observational study.
    Soto Guerrero Y; Hernández Castillo R; Santiago E; Ramírez Yuch N; Jaume Anselmi F; Jové R; Flores R; Lebrón R; Ramírez Rivera J
    Bol Asoc Med P R; 2012; 104(3):10-4. PubMed ID: 23156886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vancomycin use and antimicrobial resistance in hemodialysis centers.
    Tokars JI
    Am J Kidney Dis; 1998 Sep; 32(3):521-3. PubMed ID: 9740174
    [No Abstract]   [Full Text] [Related]  

  • 20. Practical vancomycin dosing in hemodialysis patients in the era of emerging vancomycin resistance: a single-center experience.
    Taylor ME; Allon M
    Am J Kidney Dis; 2010 Jun; 55(6):1163-5. PubMed ID: 20497837
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.